Snowball logo
logo
MDNA_logo

Medicenna Therapeutics Corp

-- $$0.00  (0%)
Estimate
EPS
-0.09
Growth
Net income, YoY
-251.89%
FCF, YoY
10.95%
Forecast
EPS (FWD)
-0.21
About the company
Ticker
MDNA
ISIN
CA58490H1073
Country
Canada
Sector (GICS)
Healthcare
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Frequently asked questions

What sector does Medicenna Therapeutics Corp (MDNA) operate in?

Medicenna Therapeutics Corp belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Medicenna Therapeutics Corp (MDNA) Earnings Per Share (EPS)?

The trailing EPS is -$0.09, and the forward EPS is -$0.21.

What is Medicenna Therapeutics Corp (MDNA) EBITDA?

Medicenna Therapeutics Corp EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.81 million.

Does Medicenna Therapeutics Corp (MDNA) pay dividends?

No. Medicenna Therapeutics Corp does not pay a dividend.

When is Medicenna Therapeutics Corp (MDNA) next earnings report?

Medicenna Therapeutics Corp is expected to release its next earnings report on December 31, 2023.